ATE284387T1 - 3-(3-chloro-4-hydroxyphenylamino)-4-(2- nitrophenyl)-1h-pyrrol-2,5-dion als glykogen synthase kinase-3 inhibitor (gsk-3) - Google Patents
3-(3-chloro-4-hydroxyphenylamino)-4-(2- nitrophenyl)-1h-pyrrol-2,5-dion als glykogen synthase kinase-3 inhibitor (gsk-3)Info
- Publication number
- ATE284387T1 ATE284387T1 AT99947744T AT99947744T ATE284387T1 AT E284387 T1 ATE284387 T1 AT E284387T1 AT 99947744 T AT99947744 T AT 99947744T AT 99947744 T AT99947744 T AT 99947744T AT E284387 T1 ATE284387 T1 AT E284387T1
- Authority
- AT
- Austria
- Prior art keywords
- hydroxyphenylamino
- gsk
- pyrrol
- dione
- nitrophenyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
- C07D207/444—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5
- C07D207/456—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9821974.4A GB9821974D0 (en) | 1998-10-08 | 1998-10-08 | Novel method and compounds |
| GBGB9827521.7A GB9827521D0 (en) | 1998-12-14 | 1998-12-14 | Novel method and compounds |
| GBGB9827883.1A GB9827883D0 (en) | 1998-12-17 | 1998-12-17 | Novel compounds |
| GBGB9905518.8A GB9905518D0 (en) | 1999-03-10 | 1999-03-10 | Novel method and compound |
| GBGB9907086.4A GB9907086D0 (en) | 1999-03-26 | 1999-03-26 | Novel compounds |
| GBGB9919362.5A GB9919362D0 (en) | 1999-08-16 | 1999-08-16 | Novel method and compounds |
| PCT/GB1999/003280 WO2000021927A2 (en) | 1998-10-08 | 1999-10-05 | Pyrrole-2,5-diones as gsk-3 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE284387T1 true ATE284387T1 (de) | 2004-12-15 |
Family
ID=27547324
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT99947744T ATE284387T1 (de) | 1998-10-08 | 1999-10-05 | 3-(3-chloro-4-hydroxyphenylamino)-4-(2- nitrophenyl)-1h-pyrrol-2,5-dion als glykogen synthase kinase-3 inhibitor (gsk-3) |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP1119548B1 (de) |
| JP (1) | JP2002527419A (de) |
| AR (1) | AR020727A1 (de) |
| AT (1) | ATE284387T1 (de) |
| AU (1) | AU6111699A (de) |
| DE (1) | DE69922526T2 (de) |
| ES (1) | ES2234300T3 (de) |
| HK (1) | HK1038564A1 (de) |
| MA (1) | MA26697A1 (de) |
| PE (1) | PE20001093A1 (de) |
| WO (1) | WO2000021927A2 (de) |
Families Citing this family (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI263636B (en) * | 1999-09-16 | 2006-10-11 | Ciba Sc Holding Ag | Fluorescent maleimides and use thereof |
| JP2003520226A (ja) | 2000-01-21 | 2003-07-02 | ノバルティス アクチエンゲゼルシャフト | ジペプチジルペプチダーゼ−ｉｖ阻害剤および抗糖尿病薬剤を含む組合せ物 |
| GB0008264D0 (en) * | 2000-04-04 | 2000-05-24 | Smithkline Beecham Plc | Novel method and compounds |
| ES2166328B1 (es) * | 2000-05-11 | 2003-09-16 | Consejo Superior Investigacion | Inhibidores heterociclicos del enzima gsk 3 utiles en el tratamiento de procesos neurodegenerativos e hiperproliferativos |
| DE60129222T2 (de) | 2000-05-11 | 2008-03-06 | Consejo Superior de Investigaciónes Científicas | Heterocyclischen inhibitoren von glycogen synthase kinase gsk-3 |
| CA2417277A1 (en) * | 2000-07-27 | 2002-02-07 | F. Hoffmann-La Roche Ag | 3-indolyl-4-phenyl-1h-pyrrole-2,5-dione derivatives as inhibitors of glycogen synthase kinase-3.beta. |
| PT1337527E (pt) * | 2000-11-07 | 2009-12-10 | Novartis Ag | Derivados de indolilmaleimida como inibidores da proteína quinase c |
| ATE326464T1 (de) * | 2000-12-08 | 2006-06-15 | Ortho Mcneil Pharm Inc | Indazolyl-substituierte pyrrolidin-verbindungen als kinase inhibitoren |
| AUPR213700A0 (en) | 2000-12-18 | 2001-01-25 | Biota Scientific Management Pty Ltd | Antiviral agents |
| GB0103031D0 (en) * | 2001-02-07 | 2001-03-21 | Smithkline Beecham Plc | Novel treatment |
| DE60209471D1 (de) * | 2001-03-29 | 2006-04-27 | Topo Target As Copenhagen Koeb | Succinimid- und maleimidderivate und ihre verwendung als katalytische inhibitoren der topoisomerase ii |
| US20040106794A1 (en) | 2001-04-16 | 2004-06-03 | Schering Corporation | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands |
| US7132445B2 (en) | 2001-04-16 | 2006-11-07 | Schering Corporation | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands |
| EP1417188A1 (de) * | 2001-08-03 | 2004-05-12 | Novo Nordisk A/S | Neue 2-4-diaminothiazolderivaten |
| TW201041580A (en) | 2001-09-27 | 2010-12-01 | Alcon Inc | Inhibitors of glycogen synthase kinase-3 (GSK-3) for treating glaucoma |
| JP2005505595A (ja) | 2001-10-12 | 2005-02-24 | シェーリング コーポレイション | Ｃｘｃ−ケモカインレセプターアンタゴニストとしての３，４−二置換マレイミド化合物 |
| US6878709B2 (en) | 2002-01-04 | 2005-04-12 | Schering Corporation | 3,4-di-substituted pyridazinediones as CXC chemokine receptor antagonists |
| CN100409840C (zh) * | 2002-01-10 | 2008-08-13 | 霍夫曼-拉罗奇有限公司 | GSK-3β抑制剂在制备增加骨生成的药物中的应用 |
| CN1649616A (zh) * | 2002-03-01 | 2005-08-03 | 希龙公司 | 治疗缺血的方法和组合物 |
| ATE478666T1 (de) | 2002-03-01 | 2010-09-15 | Takeda Pharmaceutical | Antidepressivum |
| BR0308739A (pt) | 2002-03-18 | 2005-01-11 | Schering Corp | Tratamentos em combinação para doenças mediadas por quimiocina |
| SI1499311T1 (sl) * | 2002-03-29 | 2010-03-31 | Novartis Vaccines & Diagnostic | Substituirani benzazoli in njihova uporaba kot inhibitorji Raf kinaze |
| ATE387444T1 (de) | 2002-05-08 | 2008-03-15 | Janssen Pharmaceutica Nv | Substituierte pyrroline als kinase inhibitoren |
| WO2003104222A1 (en) | 2002-06-05 | 2003-12-18 | Janssen Pharmaceutica N.V. | Bisindolyl-maleimid derivatives as kinase inhibitors |
| AU2003240517A1 (en) | 2002-06-05 | 2003-12-22 | Janssen Pharmaceutica N.V. | Substituted pyrrolines as kinase inhibitors |
| CN101037438A (zh) * | 2002-08-02 | 2007-09-19 | 沃泰克斯药物股份有限公司 | 用作gsk－3的抑制剂的吡唑组合物 |
| ATE422203T1 (de) | 2002-10-09 | 2009-02-15 | Schering Corp | Thiadiazoldioxide und thiadiazoloxide als cxc- und cc-chemokinrezeptor liganden |
| PL376301A1 (en) * | 2002-10-24 | 2005-12-27 | Sterix Limited | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 and type 2 |
| GB0224830D0 (en) | 2002-10-24 | 2002-12-04 | Sterix Ltd | Compound |
| US7144911B2 (en) | 2002-12-31 | 2006-12-05 | Deciphera Pharmaceuticals Llc | Anti-inflammatory medicaments |
| US7279576B2 (en) | 2002-12-31 | 2007-10-09 | Deciphera Pharmaceuticals, Llc | Anti-cancer medicaments |
| WO2005024755A2 (en) * | 2002-12-31 | 2005-03-17 | Deciphera Pharmaceuticals, Llc. | Medicaments for the treatment of neurodegenerative disorders or diabetes |
| US7202257B2 (en) | 2003-12-24 | 2007-04-10 | Deciphera Pharmaceuticals, Llc | Anti-inflammatory medicaments |
| GB0303319D0 (en) | 2003-02-13 | 2003-03-19 | Novartis Ag | Organic compounds |
| EP1611132A1 (de) | 2003-03-27 | 2006-01-04 | Janssen Pharmaceutica N.V. | Substituierte pyrrolinkinase-hemmer |
| EP1654255B1 (de) | 2003-06-13 | 2008-08-27 | Janssen Pharmaceutica N.V. | Substituierte indazolyl(indolyl)maleimid-derivate als kinase inhibitoren |
| GB0316232D0 (en) * | 2003-07-11 | 2003-08-13 | Astrazeneca Ab | Therapeutic agents |
| GB0316237D0 (en) * | 2003-07-11 | 2003-08-13 | Astrazeneca Ab | Therapeutic agents |
| US7338968B2 (en) | 2003-12-19 | 2008-03-04 | Schering Corporation | Thiadiazoles AS CXC- and CC- chemokine receptor ligands |
| CA2550540A1 (en) | 2003-12-22 | 2005-07-28 | Schering Corporation | Isothiazole dioxides as cxc- and cc- chemokine receptor ligands |
| JP4875978B2 (ja) * | 2004-03-15 | 2012-02-15 | 武田薬品工業株式会社 | アミノフェニルプロパン酸誘導体 |
| EP1742911A1 (de) * | 2004-04-26 | 2007-01-17 | AstraZeneca AB | 3,4-disubstituierte maleimide zur verwendung als gefässschädigende mittel |
| WO2005107465A1 (en) * | 2004-05-12 | 2005-11-17 | Bayer Cropscience Gmbh | Plant growth regulation |
| WO2006061212A1 (en) | 2004-12-08 | 2006-06-15 | Johannes Gutenberg-Universität Mainz | 3-(indolyl)-4-arylmaleimide derivatives and their use as angiogenesis inhibitors |
| SE0500058D0 (sv) * | 2005-01-10 | 2005-01-10 | Astrazeneca Ab | Therapeutic agents 5 |
| SE0500056D0 (sv) * | 2005-01-10 | 2005-01-10 | Astrazeneca Ab | Therapeutic agents 4 |
| SE0500055D0 (sv) | 2005-01-10 | 2005-01-10 | Astrazeneca Ab | Therapeutic agents 3 |
| WO2006073363A1 (en) * | 2005-01-10 | 2006-07-13 | Astrazeneca Ab | Derivatives of isothiazol-3(2h)-one 1,1-dioxides as liver x receptor modulators |
| WO2006073364A1 (en) * | 2005-01-10 | 2006-07-13 | Astrazeneca Ab | Derivatives of isothiazol-3 (2h)-thione 1,1-dioxides as liver x receptor modulators |
| ES2353401T3 (es) | 2005-06-29 | 2011-03-01 | Schering Corporation | Oxidiazolopirazinas y tiadiazolopirazinas 5,6-di-sustituidas como ligandos del receptor de cxc-quimiocina. |
| JP2009500334A (ja) | 2005-06-29 | 2009-01-08 | シェーリング コーポレイション | Ｃｘｃ−ケモカインレセプターリガンドとしてのジ置換オキサジアゾール |
| JP2009506069A (ja) | 2005-08-26 | 2009-02-12 | ブレインセルス，インコーポレイティド | ムスカリン性受容体調節による神経発生 |
| EP2258359A3 (de) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenese durch Modulation des Muscarinrezeptors mit Sabcomelin |
| PE20070458A1 (es) | 2005-09-14 | 2007-07-05 | Takeda Pharmaceutical | Composicion farmaceutica que comprende 2-[[6-(3r)-3-amino-1-piperidinil]-3,4-dihidro-3-metil-2,4-dioxo-1(2h)-pirimidinil]metil]-benzonitrilo como inhibidor de dipeptidil peptidasa |
| AU2006304787A1 (en) | 2005-10-21 | 2007-04-26 | Braincells, Inc. | Modulation of neurogenesis by PDE inhibition |
| CA2625210A1 (en) | 2005-10-31 | 2007-05-10 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
| US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| EP2377531A2 (de) | 2006-05-09 | 2011-10-19 | Braincells, Inc. | Neurogenese mittels Angiotensin-Modulation |
| US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
| US20100216805A1 (en) | 2009-02-25 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| WO2011041293A1 (en) | 2009-09-30 | 2011-04-07 | Takeda Pharmaceutical Company Limited | Pyrazolo [1, 5-a] pyrimidine derivatives as apoptosis signal-regulating kinase 1 inhibitors |
| EP2343291A1 (de) | 2009-12-18 | 2011-07-13 | Johannes Gutenberg-Universität Mainz | 3-(Indolyl)- oder 3-(Azaindolyl)-4-Arylmaleimid-Verbindungen und ihre Verwendung bei der Behandlung von Tumoren |
| WO2011097079A1 (en) | 2010-02-03 | 2011-08-11 | Takeda Pharmaceutical Company Limited | Apoptosis signal-regulating kinase 1 inhibitors |
| SG10201509157QA (en) * | 2010-11-09 | 2015-12-30 | Fujian Haixi Pharmaceuticals Inc | Compound for increasing kinase active and application thereof |
| EP2474541A1 (de) | 2010-12-23 | 2012-07-11 | Johannes- Gutenberg-Universität Mainz | Konjugierte 3-(Indolyl)- und 3-(Azaindolyl)-4-arylmaleinimid-Verbindungen und deren Verwendung bei der Behandlung von Tumoren |
| US8461179B1 (en) | 2012-06-07 | 2013-06-11 | Deciphera Pharmaceuticals, Llc | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
| WO2014204585A1 (en) * | 2013-05-03 | 2014-12-24 | The Brigham And Women's Hospital, Inc. | Methods for treatment of cardiomyopathy |
| WO2016008966A1 (en) | 2014-07-17 | 2016-01-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for treating neuromuscular junction-related diseases |
| WO2016207366A1 (en) | 2015-06-26 | 2016-12-29 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of viral infections |
| US20180256623A1 (en) * | 2015-09-16 | 2018-09-13 | University Of Virginia Patent Foundation | Compositions and method for regulating adipose tissue lipolysis, insulin-resistance, and hyperglycemia |
| CA2998827A1 (en) * | 2015-09-24 | 2017-03-30 | Glaxosmithkline Intellectual Property (No.2) Limited | Modulators of indoleamine 2,3-dioxygenase |
| EP3187495A1 (de) | 2015-12-30 | 2017-07-05 | Johannes Gutenberg-Universität Mainz | 3-(5-fluorindolyl)-4-arylmaleimid-verbindungen und deren verwendung bei der tumorbehandlung |
| KR101702897B1 (ko) * | 2016-04-15 | 2017-02-06 | 가톨릭대학교 산학협력단 | 바이오틴이 결합된 카페인산 화합물을 유효성분으로 함유하는 통풍 예방 또는 치료용 조성물 |
| CN106188007B (zh) * | 2016-06-29 | 2018-08-14 | 东华大学 | 一种3-哌啶基-4-吲哚马来酰亚胺类化合物及其制备和应用 |
| MX2022001863A (es) | 2019-08-12 | 2022-05-30 | Deciphera Pharmaceuticals Llc | Metodos para tratar los tumores del estroma gastrointestinal. |
| WO2021030405A1 (en) | 2019-08-12 | 2021-02-18 | Deciphera Pharmaceuticals, Llc | Ripretinib for treating gastrointestinal stromal tumors |
| RS65058B1 (sr) | 2019-12-30 | 2024-02-29 | Deciphera Pharmaceuticals Llc | Formulacije inhibitora amorfne kinaze i postupci njihove primene |
| BR112022013169A2 (pt) | 2019-12-30 | 2022-09-13 | Deciphera Pharmaceuticals Llc | Composições de 1-(4-bromo-5-(1-etil-7-(metilamino)-2-oxo-1,2-diidro-1,6-naftiridin-3-il)-2-fluorofeil)-3-fenilurea |
| US11779572B1 (en) | 2022-09-02 | 2023-10-10 | Deciphera Pharmaceuticals, Llc | Methods of treating gastrointestinal stromal tumors |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3335147A (en) * | 1965-04-29 | 1967-08-08 | Us Vitamin Pharm Corp | Anilino-pyridinium-maleimides |
| CZ280738B6 (cs) * | 1988-02-10 | 1996-04-17 | F. Hoffmann - La Roche And Co., Aktiengesellschaft | Substituované pyrroly, jejich použití pro výrobu léčiv a léčiva na jejich bázi |
| DE4005969A1 (de) * | 1990-02-26 | 1991-08-29 | Boehringer Mannheim Gmbh | Neue trisubstituierte pyrrole, verfahren zu ihrer herstellung sowie arzneimittel, die diese verbindungen enthalten |
| DE4005970A1 (de) * | 1990-02-26 | 1991-08-29 | Boehringer Mannheim Gmbh | Neue trisubstituierte maleinimide, verfahren zu ihrer herstellung sowie arzneimittel, die diese verbindungen enthalten |
| WO1997041854A1 (en) * | 1996-05-07 | 1997-11-13 | The Trustees Of The University Of Pennsylvania | Inhibitors of glycogen synthase kinase-3 and methods for identifying and using the same |
| DE19637042A1 (de) * | 1996-09-12 | 1998-03-19 | Boehringer Mannheim Gmbh | Heterocyclische Verbindungen und deren Verwendung in der Detektion von Nucleinsäuren |
| US6153618A (en) * | 1996-10-11 | 2000-11-28 | Chiron Corporation | Inhibitors of glycogen synthase 3 kinase |
| AU752464B2 (en) * | 1998-05-04 | 2002-09-19 | Zentaris Gmbh | Indole derivatives and their use in the treatment of malignant and other diseases caused by pathological cell proliferation |
| ID27510A (id) * | 1998-07-30 | 2001-04-12 | Japan Tobacco Inc | Senyawa malimida tersubstitusi dan penggunaan farmasinya |
-
1999
- 1999-10-05 AT AT99947744T patent/ATE284387T1/de not_active IP Right Cessation
- 1999-10-05 WO PCT/GB1999/003280 patent/WO2000021927A2/en active IP Right Grant
- 1999-10-05 AU AU61116/99A patent/AU6111699A/en not_active Abandoned
- 1999-10-05 EP EP99947744A patent/EP1119548B1/de not_active Expired - Lifetime
- 1999-10-05 ES ES99947744T patent/ES2234300T3/es not_active Expired - Lifetime
- 1999-10-05 DE DE69922526T patent/DE69922526T2/de not_active Expired - Fee Related
- 1999-10-05 JP JP2000575836A patent/JP2002527419A/ja active Pending
- 1999-10-06 MA MA25810A patent/MA26697A1/fr unknown
- 1999-10-06 AR ARP990105056A patent/AR020727A1/es unknown
- 1999-10-06 PE PE1999001014A patent/PE20001093A1/es not_active Application Discontinuation
-
2002
- 2002-01-11 HK HK02100210.2A patent/HK1038564A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AR020727A1 (es) | 2002-05-29 |
| ES2234300T3 (es) | 2005-06-16 |
| WO2000021927A3 (en) | 2000-07-13 |
| EP1119548A1 (de) | 2001-08-01 |
| WO2000021927A2 (en) | 2000-04-20 |
| DE69922526T2 (de) | 2005-06-02 |
| MA26697A1 (fr) | 2004-12-20 |
| DE69922526D1 (de) | 2005-01-13 |
| PE20001093A1 (es) | 2000-12-22 |
| JP2002527419A (ja) | 2002-08-27 |
| AU6111699A (en) | 2000-05-01 |
| EP1119548B1 (de) | 2004-12-08 |
| HK1038564A1 (zh) | 2002-03-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE284387T1 (de) | 3-(3-chloro-4-hydroxyphenylamino)-4-(2- nitrophenyl)-1h-pyrrol-2,5-dion als glykogen synthase kinase-3 inhibitor (gsk-3) | |
| ATE284885T1 (de) | 3-indolyl-4-phenyl-1h-pyrrol-2,5-dion derivate als glycogen synthase kinase 3beta inhibitoren | |
| IL158168A0 (en) | 5-membered, nitrogen-containing heterocyclic compounds and pharmaceutical compositions containing the same | |
| ATE327988T1 (de) | Chemokine rezeptor bindende heterozyklische verbindungen | |
| DE60003709D1 (de) | Substituierte azole | |
| EE200000437A (et) | Tselekoksiibiühendid | |
| HK1057890A1 (en) | Pyrazole compounds useful as protein kinase inhibitors. | |
| MXPA03005612A (es) | Compuestos de pirazol utiles como inhibidores de la proteina cinasa. | |
| ATE506950T1 (de) | Zusammensetzungen enthaltend metronidazol | |
| IL161784A0 (en) | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | |
| DK1471065T3 (da) | Hidtil ukendt 1,2,4-triazolforbindelse | |
| HK1080843A1 (en) | (3z)-3-(3-hydro-isobenzofuran-1-ylidene)-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors | |
| IL152979A0 (en) | Heterocyclic compounds | |
| IS6530A (is) | Áfangaalkýlering á 5-setnum 1-(4-flúorófenýl)-1,3-díhýdróísóbensófúrönum | |
| DK1178990T3 (da) | Imidazodiazepinderivat. | |
| ATE304289T1 (de) | Fungizide zusammensetzungen enthaltend fludioxonil | |
| DE60208451D1 (de) | Furnierschälmaschine | |
| IL155706A0 (en) | Process for the preparation of (r)-5-(2-benzenesulfonylethyl)-3-(n-methylpyrrolidin-2-ylmethyl)-1h-indole | |
| MA26860A1 (fr) | Pyrroles substitues. | |
| PT1123281E (pt) | Compostos 3-(fenil substituido)-5-(ciclopropil substituido)1,2,4-triazole | |
| FI20000421A0 (fi) | Nukleotidejä sisältävien yhdisteiden kuljetukseen käyttökelpoisia 1,4-Dihydropyridiinijohdannaisia | |
| ZA200301399B (en) | Chemokine receptor binding heterocyclic compounds. | |
| AUPR195500A0 (en) | N-containing heterocyclic compounds | |
| AU9462801A (en) | Chemokine receptor binding heterocyclic compounds | |
| PL359523A1 (en) | Chemokine receptor binding heterocyclic compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |